CurveBeam AI unlocks $696K raise as China clears its CT scanner
What's the deal? CurveBeam AI has secured approval from China's National Medical Products Administration (NMPA) for its HiRise weight-bearing CT system, triggering an additional US$647.1K (≈$696,000) equity investment from Chinese partner Shandong WeiYing Intelligent Medical TechnologyDealroom has a profile for this one. Try Dealroom →. The post-IPO shares will be issued at US$0.26 each.
What does it do? HiRise provides three-dimensional weight-bearing CT imaging of the lower extremities, letting clinicians evaluate musculoskeletal anatomy under physiological load. The NMPA sign-off clears the system for commercial sales across China.
Why now? The approval arrived ahead of timeline expectations set in the October 2025 agreements, and it was the specific milestone that released the latest tranche of capital.
What's the endgame? In October 2025, CurveBeam signed 10-year agreements with WeiYing covering exclusive distribution, marketing, and local manufacturing of its weight-bearing CT systems across China, Hong Kong, Macau, and Taiwan. WeiYing — a joint venture involving Shandong Weigao Haixing Medical DeviceDealroom has a profile for this one. Try Dealroom → (Wego) and other partners — committed to investing up to US$6.47M, tied to regulatory, commercial, and product milestones.
An initial US$2.59M linked to the licence agreements was received in February. The remaining capital follows further milestones, and CurveBeam says it will confirm the placement's timing in due course.
What's next? CurveBeam and Wego OrthopedicsDealroom has a profile for this one. Try Dealroom → will prioritise commercial launch, expand the distribution pipeline, and advance local manufacturing in China — a step the company says could improve cost competitiveness and strengthen its supply chain.
The signal: By tying funding to regulatory wins, CurveBeam is converting a strategic agreement into cash and commercial access in one of the world's largest medical device markets — each milestone both proof of progress and a drawdown on committed capital.
Read more: kalkinemedia.com
